Navigation Links
Bioartificial kidney under study at MCG

Whether a bioartificial kidney containing billions of donor kidney cells will help intensive care patients with kidney failure survive is under study at the Medical College of Georgia.

MCG Medical Center has joined a study taking place in intensive care units across the country to evaluate the efficacy of the renal assist device, says Dr. Harold M. Szerlip, MCG nephrologist specializing in acute renal failure and a principal investigator on the study.

"If you have renal failure in the ICU, your mortality is extremely high," Dr. Szerlip says. "Anywhere from 50 to 70 percent of those patients die and over the past 20 years, despite dialysis, that has not changed much."

He hopes the new device, developed by Dr. H. David Humes at the University of Michigan, can help turn the tide for some patients by more closely mimicking the many important functions of the kidney.

In ICUs today, doctors may opt for newer continuous dialysis therapies in which patients with renal failure receive dialysis around the clock. With more standard intermittent therapy, patients get several hours of dialysis three to four times a week.

Since kidneys are constantly working, it may seem logical that longer dialysis is a better option, but, in fact, the issue has not been scientifically analyzed. This month, Dr. Szerlip and MCG Medical Center will join a Department of Veterans Affairs and National Institutes of Health study to do just that.

But no matter how long dialysis is given, it only replicates a fraction of the work of the kidneys, which are involved in diverse functions ranging from regulating vitamin D to modulating the immune response. "Existing forms of dialysis have only replaced the ability of the kidneys to rid the body of waste products and correct abnormalities in blood chemistry; they don't replace kidney function, " says Dr. Szerlip.

The kidneys also secrete hormones, help determine how the body metabolizes calcium and phosp
'"/>

Source:Medical College of Georgia


Page: 1 2 3

Related biology news :

1. Deficiency of growth hormone and IGF-1 reduces cancer and kidney disease, but creates other problems
2. NASA links nanobacteria to kidney stones and other diseases
3. New type of rejection blocker protects kidneys after transplant
4. New research demonstrates bone-marrow derived stem cells can reverse genetic kidney disease
5. Scientists discover that widely available drug also helps fight kidney disease
6. Gene discovery may shed light on kidney disease
7. U of M study examines kidney stone prevention in astronauts
8. Scientists solve 30-year-old mystery of mutant mouses kidney woes
9. More kidney cancer is detected and treated early, yet death rate rises
10. Key gene controlling kidney development found
11. Mutant gene causes severe kidney disease in infants
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Bioartificial kidney under study MCG

(Date:5/29/2015)... DUBLIN , May 28, 2015 ... the addition of the "Facial Recognition Market ... User - Global Forecast to 2020" report ... years, have seen facial recognition technology become more ... technology to gain traction and investment from the ...
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... Goldfarb LLP is investigating whether the board of ... shareholder protection laws as evidenced through alleged inconsistencies in ... stock before June 15, 2012 are encouraged to contact ... about their rights and remedies. "On ...
... Athens, Ga. University of Georgia scientists have discovered ... the immune system. Kimberly Klonowski, assistant professor of cellular ... Sciences, and her colleagues found that administering a cell-signaling ... reduces their peak viral load by nearly three times. ...
... Research Centre of Finland in collaboration with the University ... signature which predicts progression to Alzheimer,s disease months or ... occur. The goal of the new collaboration between VTT ... a large patient cohort as well as to discover ...
Cached Biology News:UGA study reveals flu-fighting role for well-known immune component 2VTT and GE Healthcare developing novel biomarkers to predict Alzheimer's disease 2
(Date:5/29/2015)... 29, 2015 The changing healthcare landscape ... involving clinical development, regulatory compliance and market education. ... Medical Affairs has faced many challenges in creating ... And while its importance is recognized internally, Medical ... strong performance metrics to demonstrate the value of ...
(Date:5/29/2015)... , May 29, 2015 In recent years, ... availability of Big Data that can generate valuable insights. ... with utilizing Big Data have caused the biopharmaceutical sector ... industries. According to a recent study ... already have a Big Data team or function in ...
(Date:5/29/2015)... 29, 2015 BerGenBio AS ("BerGenBio" ... that an abstract on the latest data on BGB324, ... Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking ... published in conjunction with the 2015 American Society of ... , May 29 - June 2, 2015. ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 ... multi-drug-resistant organisms (MDROs), announced that initial feasibility data ... bacterial detection and susceptibility testing from positive blood ... on May 31, 2015 in New Orleans, LA. ... of molecular diagnostics that can quickly detect bacteria ...
Breaking Biology Technology:Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3
... N.Y. , July 29 On ... Publication Professionals (ISMPP) and the Medical Publishing Insights and ... various MPIP initiatives ( http://www.mpip-initiative.org ). The web page ... MPIP initiative, updating viewers on new or planned activities, ...
... , Saliva-Based DNA Collection Product Chosen for Study to Identify ... , , ... /PRNewswire/ - DNA Genotek, a leading provider of products ... the world,s leading TB vaccine research site, the South African ...
... , VANCOUVER , July 28 ... ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) ... trial of MultiStem(R), its allogeneic cell therapy product, ... more commonly referred to as a heart attack. ...
Cached Biology Technology:ISMPP and MPIP Announce New Medical Publishing Website 2ISMPP and MPIP Announce New Medical Publishing Website 3DNA Genotek's Oragene-DNA Achieves 95% Compliance Rate in South African Tuberculosis Vaccine Initiative (SATVI) 2DNA Genotek's Oragene-DNA Achieves 95% Compliance Rate in South African Tuberculosis Vaccine Initiative (SATVI) 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 2Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 4Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 6Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 7Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 8Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 9